Exploring the Combined Action of Adding Pertuzumab to Branded Trastuzumab versus Trastuzumab Biosimilars for Treating HER2+ Breast Cancer

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Detalhes bibliográficos
Autores: Franco-Mateos, Emma, Souza-Egipsy, Virginia, García-Estévez, Laura, Pérez-García, José, Gion, María, Garrigós, Laia, Cortez, Patricia, Saavedra, Cristina, Gómez, Patricia, Ortiz, Carolina, Cruz, Víctor L., Ramos, Javier, Cortés, Javier, Vega, Juan Francisco
Tipo de documento: artigo
Estado:Versão publicada
Data de publicação:2024
País:España
Recursos:Consejo Superior de Investigaciones Científicas (CSIC)
Repositório:DIGITAL.CSIC. Repositorio Institucional del CSIC
OAI Identifier:oai:digital.csic.es:10261/352833
Acesso em linha:http://hdl.handle.net/10261/352833
Access Level:Acceso aberto
Palavra-chave:HER2+ breast cancer
Monoclonal antibodies
Trastuzumab biosimilars
Descrição
Resumo:© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Registros relacionados